Croma-Pharma GmbH Announces Strategic Milestone as Novaestiq Corp. Joins Waldencast
Croma-Pharma GmbH Announces Strategic Milestone as Novaestiq Corp. Joins Waldencast
We’re proud to announce that Novaestiq Corp., a joint venture of Croma-Pharma and Gore Range Capital, is now part of Waldencast. This marks a major step in our global growth strategy.
Our innovative Saypha® ChIQ™ and MagIQ™ HA injectables will launch in the U.S. under the Obagi Medical brand—backed by world-class science, high safety standards, and a legacy of over 110 million syringes produced across 80+ markets.
This partnership accelerates our mission to deliver high-quality, minimally invasive aesthetic solutions worldwide.
